News
Sexual wellness start-up bags US$1.2m investment
Founder Lyndsey Harper aims to empower women to talk about sexual health issues
The US sexual wellness start-up Rosy has bagged a US$1.2m investment to “revolutionise” sexual health education.
Rosy, a sexual wellness-focused app and media platform led by CEO and founder Dr Lyndsey Harper, aims to grant women access to information and interventions to solve their sexual health problems.
A board-certified OB/GYN, Harper started Rosy after recognising that 43 per cent of women had a sexual health problem but were met with a complete lack of resources when trying to solve these important issues.
She launched the platform in 2019 with the goal of putting sexual health education and tools in the hands of women everywhere.
As of February, more than eight per cent of OB/GYNs across the US are referring patients to Rosy, which serves around 150,000 women.
“Rosy has redefined the landscape of women’s sexual health. We’re now expanding into B2B partnerships that will allow us to take this mission even further,” said Harper.
“Rosy’s data set is likely the largest in the field of women’s sexual health and we will use the power of these solutions to create an even more robust experience for our members and partners beyond what we could have imagined a few years ago.”
The company will use the fresh funding to extend its reach into other areas of women’s health and explore various partnerships.
Its founder has previously said she created Rosy with the aim to “revolutionise” the way women and their providers think about, talk about, and treat women’s sexual problems.
“For men, sexual health and overall health have always been linked. At Rosy, our goal is to finally treat women’s sexual health as a crucial aspect of their overall wellbeing,” Harper said.
“It’s time women feel empowered to talk about sexual health issues and have access to convenient solutions.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







1 Comment